Rockefeller Capital Management
SGMT icon

Rockefeller Capital Management’s Sagimet Biosciences SGMT Stock Holding History

Rockefeller Capital Management’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-9,000
Closed -$47K – 4858
2026
Q1 		$47K Hold
9,000
– – ﹤0.01% 3311
2025
Q4 		$53.3K Hold
9,000
– – ﹤0.01% 3034
2025
Q3 		$61.7K Buy
+9,000
New +$73K ﹤0.01% 2802

Other funds holding SGMT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Rockefeller Capital Management's SGMT Position: Q2 2026 in Review

Rockefeller Capital Management sold out of Sagimet Biosciences (SGMT) in Q2 2026, closing a stake of 9,000 shares — an estimated $47K sold.

Rockefeller Capital Management first reported a position in SGMT in Q3 2025 and held it in 3 quarters. The position peaked at $61.7K in Q3 2025. 122 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

  • Rockefeller Capital Management reported no remaining Sagimet Biosciences position as of Q2 2026 after selling out during the quarter.
  • Rockefeller Capital Management sold 9,000 Sagimet Biosciences shares in Q2 2026, an estimated $47K.
  • Rockefeller Capital Management first reported a position in Sagimet Biosciences in Q3 2025 and held it in 3 quarters.
  • Rockefeller Capital Management's Sagimet Biosciences position peaked at $61.7K in Q3 2025.
  • 122 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.